IFN-alpha2b and thalidomide synergistically inhibit tumor-induced angiogenesis
| Autor: | Barbara S. Jacobs, Ernest C. Borden, Daniel J. Lindner, Joseph A. Bauer, Bei H. Morrison, Ronald W. Grane |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Male
Angiogenesis Immunology Transplantation Heterologous Alpha interferon Mice Nude Angiogenesis Inhibitors Antineoplastic Agents Pharmacology Interferon alpha-2 Drug Administration Schedule Metastasis Polyethylene Glycols Mice Dermis Virology LNCaP medicine Tumor Cells Cultured Animals Humans Neovascularization Pathologic business.industry Melanoma Interferon-alpha Drug Synergism Cell Biology Neoplasms Experimental medicine.disease In vitro Recombinant Proteins Thalidomide medicine.anatomical_structure Female business Cell Division Neoplasm Transplantation medicine.drug |
| Zdroj: | Journal of interferoncytokine research : the official journal of the International Society for Interferon and Cytokine Research. 23(1) |
| ISSN: | 1079-9907 |
| Popis: | Angiogenesis is an absolute requirement for tumor growth and metastasis. The purpose of this study was to evaluate the antiangiogenic activity of interferon-alpha2b (IFN-alpha2b) and thalidomide, as single agents and in combination. The murine dermis model was used to assess tumor-induced angiogenesis in nude mice. Human ACHN (renal), NIH-OVCAR-3 (ovarian), LNCaP (prostate), and SK-Mel-1 (melanoma) tumor cells were inoculated intradermally into the flanks of nude mice. IFN-alpha2b and thalidomide, administered daily, were effective inhibitors of angiogenesis induced by all four tumor types. The combination of IFN-alpha2b and thalidomide caused a synergistic decrease in mean vessel count in tumors that were resistant to the antiproliferative effects of IFN-alpha2b and thalidomide in vitro. This enhanced suppression of angiogenesis translated into synergistic antitumor activity in a xenograft model. Pegylated IFN-alpha (PEG-IFN-alpha2b) (10(6) U) administered once in 10 days was as effective as daily IFN-alpha2b treatment (10(6) U x 10 days). IFN-alpha2b and thalidomide have potentiated antiangiogenic activity when used in combination. A single dose of PEG-IFN-alpha2b (10(6) U) was as effective at suppressing vessel growth as an equivalent dose of IFN-alpha2b given daily for 10 days. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|